



## The spread of chloramphenicol-resistant *Neisseria meningitidis* in Southeast Asia



Elizabeth M. Batty<sup>a,b,1,\*</sup>, Tomas-Paul Cusack<sup>c,d,1</sup>, Janjira Thaipadungpanit<sup>a,e</sup>,  
Wanitda Watthanaworawit<sup>f</sup>, Verena Carrara<sup>f,g</sup>, Somsavanh Sihalath<sup>c</sup>, Jill Hopkins<sup>h</sup>,  
Sona Soeng<sup>h</sup>, Clare Ling<sup>b,f</sup>, Paul Turner<sup>b,h,2</sup>, David A.B. Dance<sup>b,c,i,2</sup>

<sup>a</sup> Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

<sup>b</sup> Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

<sup>c</sup> Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao Democratic People's Republic

<sup>d</sup> National Infection Service, Public Health England, London, United Kingdom

<sup>e</sup> Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

<sup>f</sup> Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand

<sup>g</sup> Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland

<sup>h</sup> Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodia

<sup>i</sup> Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

### ARTICLE INFO

#### Article history:

Received 16 December 2019

Received in revised form 30 March 2020

Accepted 30 March 2020

#### Keywords:

*Neisseria meningitidis*

Genomics

Antimicrobial resistance

### ABSTRACT

**Objectives:** Invasive disease caused by *Neisseria meningitidis* is a significant health concern globally, but our knowledge of the prevailing serogroups, antimicrobial susceptibility patterns, and genetics of *N. meningitidis* in Southeast Asia is limited. Chloramphenicol resistance in *N. meningitidis* has rarely been reported, but was first described in isolates from Vietnam in 1998. We aimed to characterise eight chloramphenicol resistant meningococcal isolates collected between 2007 and 2018 from diagnostic microbiology laboratories in Cambodia, Thailand and the Lao People's Democratic Republic (Laos).

**Methods:** Whole-genome sequencing was used to generate genome sequences from 18 meningococcal isolates including the eight chloramphenicol resistant isolates. We identified antimicrobial resistance genes present in these strains, and examined the phylogenetic relationships between strains.

**Results:** The eight resistant strains all contain the same chloramphenicol resistance gene first described in 1998, and are closely related to each other. Strains resistant to penicillin, tetracycline, and ciprofloxacin were also observed, including a chloramphenicol-resistant strain which has acquired penicillin and ciprofloxacin resistance.

**Conclusions:** This study suggests that chloramphenicol-resistant *N. meningitidis* is more widespread than previously thought, and that the previously-identified resistant lineage is now found in multiple countries in Southeast Asia.

© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

### Introduction

Invasive disease caused by *Neisseria meningitidis* is an important global health concern, being associated with significant rates of mortality and long-term sequelae (Vyse et al., 2013). The burden of meningococcal disease in Southeast Asia is poorly described, with few data on prevailing serogroups and antimicrobial susceptibility patterns (Vyse et al., 2011). The Mahidol-Oxford Tropical Health

Network (MORU) includes diagnostic microbiology laboratories in Thailand, Laos and Cambodia, where *N. meningitidis* is an infrequently isolated pathogen. Detection of a chloramphenicol-resistant strain of *N. meningitidis* at our laboratory site in Laos in November 2017 prompted a review of published reports of chloramphenicol resistance in *N. meningitidis* and review of chloramphenicol susceptibility amongst meningococcal isolates in our laboratory network. Although no longer standard therapy for meningococcal meningitis, chloramphenicol is commonly used in beta-lactam intolerant patients and is recommended as an alternative agent in international guidelines for treatment of meningococcal meningitis (Tunkel et al., 2004; McGill et al., 2016), and therefore resistance to this agent remains an issue of clinical importance.

\* Corresponding author at: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

E-mail address: [elizabeth.b@tropmedres.ac](mailto:elizabeth.b@tropmedres.ac) (E.M. Batty).

<sup>1</sup> These first authors contributed equally to this article.

<sup>2</sup> These senior authors contributed equally to this article.

Chloramphenicol resistance in *N. meningitidis* has rarely been reported, first being described in 1998 in 11 isolates from Vietnam and one isolate from France, due to the presence of a chloramphenicol transferase gene (*catP*) possibly derived from a *Clostridium perfringens* transposable element (Galimand et al., 1998). Two further isolates with the same *catP* insertion were later described in Australia (Shultz et al., 2003) amongst 1382 isolates. More recently, chloramphenicol resistance was reported in one of 2888 isolates in Brazil (Gorla et al., 2018), and a further highly resistant isolate was found in Vietnam in 2014 (Tran et al., 2019). Despite historical use of single-dose oily chloramphenicol for epidemic management of meningococcal meningitis (Fuller et al., 2003), we could find no reports of chloramphenicol resistance from Africa, although susceptibility information on African isolates is limited (Hedberg et al., 2009).

We identified chloramphenicol resistance in eight of 25 isolates of *N. meningitidis* in our network laboratories over an 11 year time period. Given the seemingly high frequency of chloramphenicol resistance amongst our *N. meningitidis* isolates, we aimed to characterise the genetic basis of this using whole genome sequencing. In addition, due to the scarcity of meningococcal data from Southeast Asia, we report serogroup data and phenotypic and genotypic susceptibilities to other routinely tested antimicrobial agents in 18 of these isolates that were available for sequencing.

## Methods

### Study sites

Clinical isolates from three laboratories were included. The Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos provides diagnostic microbiology services to Mahosot Hospital as well as other hospitals in Vientiane and other provincial sites. The Microbiology Laboratory of the Shoklo Malaria Research Unit (SMRU), Mae Sot, Thailand supports healthcare provision to marginalised populations on the Thailand-Myanmar border. The Cambodia-Oxford Medical Research Unit (COMRU) provides diagnostic microbiology services to the Angkor Hospital for Children, a paediatric teaching hospital in Siem Reap, Cambodia. All laboratories routinely store clinically significant bacterial isolates at  $-80^{\circ}\text{C}$ .

**Table 1**  
Clinical information on the samples.

Patient	Sample ID	Unit	Specimen date	Sample type	Age (years)	Sex	Diagnosis	Antibiotic therapy	Status at discharge
1	NM01	SMRU	25/7/07	CSF	7	M	Meningitis	Unknown	Unknown
2	NM03	SMRU	25/11/09	BC	1	F	Sepsis	Ceftriaxone	Well
3	NM04	SMRU	15/11/10	BC	<1	M	Meningitis	Ceftriaxone	Well
4	NM06	SMRU	19/6/11	BC	0.2	M	Meningitis	Unknown	Unknown
5	NM07	SMRU	4/10/11	BC	0.5	M	Meningitis	Ceftriaxone	Well
6	NM09	SMRU	7/1/12	BC	0.2	M	Meningitis	Ceftriaxone	Well
7	NM11	SMRU	18/1/12	BC	3	M	Meningitis	Ceftriaxone	Well
8	NM12	SMRU	28/12/12	BC	0.3	F	Sepsis	Ceftriaxone	Well
9	NM13	SMRU	13/5/13	BC	0.6	M	Sepsis	Ceftriaxone	Well
10	NM14	SMRU	15/2/14	BC	0.3	F	Sepsis	Ceftriaxone	Well
11	NM15	SMRU	19/12/14	BC	0.3	M	Sepsis	Unknown	Well
12	NM16	LOMWRU	10/11/17	CSF	60	F	Meningitis	Ceftriaxone	Well
13	NM18	COMRU	13/10/13	BC	0.14	F	Meningitis/Sepsis	Ceftriaxone	Well
14	NM19	COMRU	25/4/14	BC	1.84	F	Sepsis	Ceftriaxone	Well
15	NM20	COMRU	31/3/15	BC	0.91	F	Pneumonia/Sepsis	Ceftriaxone	Well
16	NM21	COMRU	24/7/16	BC	0.07	M	Meningitis/Sepsis	Unknown	Well
17	NM23	COMRU	22/8/17	BC	0.33	F	Meningitis	Ceftriaxone	Well
18	NM25	LOMWRU	21/3/18	BC	0.25	M	Meningitis	Ceftriaxone	Well

SMRU, Shoklo Malaria Research Unit, Mae Sot, Thailand; LOMWRU, Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit, Vientiane, Laos; COMRU, Cambodia Oxford Medical Research Unit, Siem Reap, Cambodia.  
CSF, cerebrospinal fluid; BC, blood culture.

### Sample selection, organism identification and phenotypic antimicrobial susceptibility testing

Laboratory records were reviewed for all clinical isolates of *N. meningitidis* up until 31st March 2018, with data available from year 2000 in LOMWRU, 2007 in SMRU and from 2013 in COMRU. A total of thirty-four isolates were identified (9 from LOMWRU, 18 from SMRU, 7 from COMRU), of which 25 had susceptibility data for chloramphenicol and were stored and viable. *N. meningitidis* isolates were originally identified by API NH (bioMérieux, France) and had undergone antimicrobial susceptibility testing (AST) by disk diffusion for chloramphenicol, ciprofloxacin and ceftriaxone, and Etest (bioMérieux, France) for penicillin, according to Clinical and Laboratory Standards Institute (CLSI) standards and break-points. Before genotypic characterisation, isolates were subcultured on to chocolate agar from storage at  $-80^{\circ}\text{C}$  and underwent confirmation of identity by MALDI-TOF (Vitek MS, bioMérieux) and AST repeated by Etest (bioMérieux, France) according to manufacturer's instructions and CLSI 2018 standards (Wayne, PA, Clinical and Laboratory Standards Institute 2018). Two isolates failed to confirm as *N. meningitidis*, and five were removed as duplicate isolates from patients in whom *N. meningitidis* was isolated from multiple sites, leaving 18 isolates for analysis.

### Patient-related metadata

Demographic data, clinical syndrome, antibiotic treatment and status on discharge were obtained from laboratory records and patient charts where available.

### Genotypic characterization

Sequencing was performed at the MORU laboratories in Bangkok, Thailand. Libraries were made from extracted DNA using the Illumina Nextera XT library preparation kit (Illumina, San Diego, CA, USA) and quantified on an Agilent BioAnalyser (Agilent Technologies, Santa Clara, CA, USA). The pooled libraries were sequenced on one run of an Illumina MiSeq sequencer using the v2 reagent kit to give 250 bp paired-end reads. The genome assembly of chloramphenicol-resistant strain DuyDNT from Vietnam was obtained from Genbank under accession RPSF00000000.

Spades v3.11.1 (Bankevich et al., 2012) was used to assemble genomes from whole-genome sequencing. Abricate v0.8.10

(Seemann, 2018a) was used to look for acquired resistance genes using the bundled ResFinder database (updated 2018-10-02) (Zankari et al., 2012). BLAST was used to search for specific antibiotic resistance genes. Prokka 1.13.3 was used to annotate the assembled genomes.

In silico serogrouping of the isolates was performed by retrieving the sequences of the genes in the capsule synthesis region of the capsule that are unique to each serogroup (*csb*, *csc*, *csw* and *csy*) for the B, C, W and Y serogroups respectively, and determining their presence or absence using BLAST to search the genome assemblies.

Snippy v4.3.6 (Seemann, 2018b) was used to call SNPs against the MC58 reference genome from raw sequence data and from the assembled DuyDNT genome. Initial phylogenetic trees were generated from the core SNP fasta files using IQ-TREE (Nguyen et al., 2015) under the GTR + F + ASC + R3model which was the best fit using BIC implemented in ModelFinder (Kalyaanamoorthy et al., 2017). The initial tree was used as input to Gubbins v2.3.1 (Croucher et al., 2015) to generate a phylogeny accounting for recombination.

## Results

### Phenotypic characteristics and patient-related data

Eighteen isolates of *N. meningitidis* (11 from Thailand, 5 from Cambodia, 2 from Laos) from 18 patients were included in the analysis (Table 1). Eight of 18 (44.4%) meningococcal isolates were resistant to chloramphenicol. Four of the resistant isolates were collected from Thailand, and two each from Cambodia and Laos. All isolates were susceptible to ceftriaxone, but 10/18 (55.5%) isolates had reduced susceptibility to penicillin, including one isolate which was resistant according to CLSI criteria (Table 2). Phenotypic ciprofloxacin resistance was detected in two isolates.

Despite COMRU being the only site with a purely paediatric population, 17/18 patients were children under 8 years old, with a median age of approximately 4 months (one patient <1 year old with no recorded date of birth was attributed the age of 1 year for the purposes of the calculation). Most patients presented with meningitis and/or sepsis, all patients with known antibiotic treatment (14/18) were treated with ceftriaxone, and all of the 16 patients with known outcome were discharged alive following clinical improvement.

### Genotypic characterization

All 18 isolates underwent sequencing. 0.4–2.4 million sequence reads were obtained from each isolate, giving 42–233X coverage of the genome. The genomes were assembled in 133–248 contigs, with a total length of 2,124,885–2,217,307 bp and n50 between 40.4 and 82.5 kb.

We determined the serogroups of the isolates from the genome assemblies by looking for the presence of the unique capsule synthesis genes for the B, C, W and Y serogroups which commonly cause invasive disease (Harrison et al., 2013). Two isolates showed the presence of the *csc* gene, indicating they are serogroup C, while the other 16 isolates, including all the resistant isolates, had the *csb* gene, indicating they are serogroup B. No matches for the serogroup W or Y genes could be found.

We determined the sequence types of the isolates in our sample set (Table 1). Of the chloramphenicol resistant isolates, five were ST-1576, one was ST-11005, and two isolates had novel sequence types (assigned as ST-14487 and ST-14496). ST-1576 and ST-11005 differ only at the *gdh* locus, and the two novel sequence types also differ from ST-1576 at only one locus. None of the chloramphenicol susceptible isolates were from ST-1576 or ST-11005, but they were from multiple sequence types, including four isolates with novel sequence types (assigned as ST-14488, ST-14489, ST-14503, and ST-14507). Two isolates from Thailand were ST-41 and ST-1145, and one was from ST-32. These sequence types are part of the ST-41/44 and ST-32 hypervirulent clonal complexes commonly seen in invasive disease (Racloz and Luiz, 2010). The novel ST-14488 sequence type was also part of the ST-41/44 complex. The ST-14503 isolate belonged to the ST-4821 clonal complex previously associated with an outbreak in China (Peng et al., 2008). The other isolates could not be assigned to a clonal complex.

By searching for the presence of antimicrobial resistance genes in the isolates, we identified a 623 bp *catP* chloramphenicol transferase gene with the same flanking sequences in all eight chloramphenicol resistant isolates. It had previously been shown that a *catP* gene was present in the highly chloramphenicol-resistant DuyDNT isolated in Vietnam in 2014, and the same *catP* gene and flanking regions also present in this isolate. By alignment of the region surrounding the *catP* gene to the MC58 reference genome, it was determined that the chloramphenicol resistance gene was found inserted between genes NMB1351 and NMB1352.

**Table 2**  
Antibiotic resistance and genetic data on the samples. Minimum inhibitory concentration for each antibiotic is shown in brackets.

Sample ID	Phenotypic antibiotic susceptibility				Genotypic antibiotic resistance	PEN phenotype/genotype discordance	Serogroup	MLST	Clonal complex
	CHL	CIP	CRO	PEN					
NM01	R (128)	S (0.004)	S (<0.016)	I (0.125)	CHL, PEN		B	1487	
NM03	S (1)	S (0.004)	S (<0.016)	I (0.25)	PEN		B	14488	ST-41/44 complex
NM04	S (2)	S (0.004)	S (<0.016)	S (0.064)			B	14489	
NM06	S (2)	S (0.004)	S (<0.016)	S (0.064)			B	32	ST-32 complex
NM07	S (1)	R (0.125)	S (<0.016)	I (0.25)	PEN, CIP, TET		C	3256	
NM09	S (2)	S (0.004)	S (<0.016)	S (0.064)			B	5604	
NM11	R 128	S (0.004)	S (<0.016)	S (0.064)	CHL		B	14496	
NM12	R (128)	S (0.004)	S (<0.016)	R (0.5)	CHL, PEN		B	1576	
NM13	R (128)	S (0.004)	S (<0.016)	S (0.064)	CHL		B	1576	
NM14	S (2)	S (0.004)	S (<0.016)	I (0.25)	PEN		B	1145	ST-41/44 complex
NM15	S (1)	S (0.008)	S (<0.016)	I (0.25)	PEN		B	41	ST-41/44 complex
NM16	R (32)	S 0.032	S (0.002)	I (0.125)	CHL	Yes	B	1576	
NM18	R (32)	R (0.25)	S (0.016)	I (0.125)	CHL, CIP, PEN		B	1576	
NM19	S (1)	S (0.008)	S (0.016)	S (0.032)			C	14503	ST-4821 complex
NM20	R (32)	S (0.016)	S (0.016)	S (0.064)	CHL, PEN	Yes	B	11005	
NM21	S (2)	S (0.016)	S (0.016)	S (0.016)			B	12811	
NM23	S (2)	S (0.016)	S (0.016)	I (0.125)	PEN		B	14507	
NM25	R (32)	S (0.004)	S (0.002)	I (0.25)	CHL, PEN		B	1576	

CHL, chloramphenicol; CIP, ciprofloxacin; CRO, ceftriaxone; PEN, penicillin; TET, tetracycline. S, susceptible; I, intermediate; R, resistant; MIC, minimum inhibitory concentration.

The *catP* gene was identical to the *catP* gene previously reported in France (Galimand et al., 1998) and a comparison of the sequences surrounding the insertion show that it was inserted in the same position in the genome (Supplementary Figure 1). The insertion is 986 bp identical to the Tn4451 transposon from *C. perfringens*, but contains only the *catP* gene and no complete flanking genes.

Ten of our isolates had reduced susceptibility or resistance to penicillin, including two of the chloramphenicol-resistant isolates (NM18 and NM25). We extracted the *penA* gene sequence to look for the five amino acid changes known to confer reduced susceptibility to penicillin (Taha et al., 2007). Nine isolates had all five amino acid changes, while the other nine isolates had none of the five changes. Concordance between the phenotypic and genotypic susceptibility was not complete – one isolate (NM16) with reduced susceptibility phenotypically did not display the amino acid changes, while one isolate (NM20) with the *penA* changes did not show phenotypic reduced susceptibility (Table 2). The isolate determined to be resistant to penicillin had the same *penA* allele as an isolate with only reduced susceptibility. The *bla<sub>ROB-1</sub>* gene is also known to confer penicillin resistance in *N.*


*meningitidis* (Tsang et al., 2019), but this gene was not present in any of our strains.

Isolate NM07 from Thailand was found to contain the tetracycline resistance gene *tetB*. NM07 and NM18, carry the *gyrA* Thr91 → Ile mutation known to cause ciprofloxacin resistance (Enríquez et al., 2008; Skoczynska et al., 2008) and are both phenotypically resistant to ciprofloxacin.

We generated a phylogeny of the 18 genomes from this study and the previously-reported DuyDNT chloramphenicol-resistant isolate (Figure 1) after removing recombinant SNPs, as *N. meningitidis* is highly recombinogenic (Feil et al., 1999). This shows that the chloramphenicol-resistant isolates from all four countries are in a single clade, with the isolates from each country clustered together within this clade.

## Discussion

We describe phenotypic and genotypic characteristics of 18 isolates of *N. meningitidis* from three countries in Southeast Asia isolated over an 11 year period. Most strikingly, chloramphenicol



**Figure 1.** A phylogeny of the 19 *Neisseria meningitidis* strains showing country of origin and resistance genotypes. The phylogeny was generated by Gubbins using RAxML and the scale bar indicates the number of SNPs.

resistance, although rarely reported in the literature, was detected in a higher proportion (44.4%) of isolates compared to studies from other regions reporting on susceptibilities of large numbers of isolates, suggesting this is proportionately more common in Southeast Asia. The identical *catP* insertion across the isolates in this study and the previously reported isolates from Vietnam and Australia suggests that chloramphenicol resistance in *N. meningitidis* was acquired once in the ST-1576 lineage, and that lineage has now spread across Southeast Asia.

A high proportion of our isolates (55.5%) displayed reduced susceptibility to penicillin, 9/10 of which had genetic markers known to confer reduced penicillin susceptibility. However, a penicillin-susceptible isolate also carried these genetic markers, although the MIC in this isolate was close to the intermediate breakpoint. There may also be further genetic determinants of resistance in these strains, as we have limited knowledge of *N. meningitidis* genomes in Southeast Asia.

We also identified isolates resistant to multiple antibiotics including an isolate resistant to chloramphenicol and ciprofloxacin with reduced susceptibility to penicillin, and the DuyDNT isolate is susceptible to ciprofloxacin but carries a tetracycline resistance gene. The first reported chloramphenicol resistant *N. meningitidis* isolates were susceptible to penicillin, tetracycline, and quinolones (Galimand et al., 1998), suggesting that this lineage has acquired resistance to multiple antibiotics during its spread.

Our isolates were predominantly serogroup B, with only two patients with strains from serogroup C. This is consistent with previous reports of serogroup B isolates causing sporadic disease in Thailand (Pancharoen et al., 2000; Borrow et al., 2017) while very little information is available about common serogroups in Laos and Cambodia.

Five of the isolates we identified come from hypervirulent clonal complexes commonly implicated in invasive disease, including the ST-32 and ST-41/44 clonal complexes involved in multiple epidemics (Harrison et al., 2009), and the ST-4821 clonal complex first identified in China in 2003 (Peng et al., 2008). The remaining thirteen isolates could not be assigned to one of these lineages, and many of these isolates were from novel sequence types. This suggests predominantly sporadic infection arising from the nasopharyngeal flora rather than an ongoing serogroup B epidemic.

There are several limitations of this study. The study involved only three sites and a relatively small number of isolates, reflecting the relative rarity of invasive meningococcal disease in our populations, giving only a snapshot of the epidemiology across the region. Furthermore, only culture-positive isolates were included, which may have underestimated the true number of cases and selected for more resistant isolates given the seemingly high prevalence of pre-hospital antibiotic treatment regionally (Khennavong et al., 2011), although relatively few additional cases were identified by routine CSF PCR for *N. meningitidis* in our laboratories. Nevertheless, our results suggest that resistance to chloramphenicol is relatively common in meningococcal isolates from Southeast Asia. This remains clinically important given the role of chloramphenicol as a common second-line agent for treatment of meningococcal meningitis. *N. meningitidis* which is non-susceptible to third-generation cephalosporins (Deghmane et al., 2017) has been recently reported in France, with a *penA* allele which may have been acquired from *Neisseria gonorrhoeae*, raising the possibility that recombination with extensively drug-resistant *N. gonorrhoeae* could result in the spread of further drug resistance in *N. meningitidis*. Our phenotypic and genotypic characterisation of isolates from three countries in Southeast Asia will add to the limited published data of the epidemiology of meningococcal disease in Southeast Asia, and aid future surveillance of drug-resistant isolates.

## Authors' contribution

DD and PT conceived the project. EMB and TPC performed data analysis and drafted the manuscript. JT, WW, VC, SS, JH, and CL performed laboratory experiments. EMB, TPC, JH, CL, PT and DD edited the final manuscript. All authors reviewed and approved the final manuscript.

## Data availability

Raw sequence data has been deposited in the European Nucleotide Archive as project PRJEB30968. Novel sequence types and isolates have been deposited in PubMLST.

## Funding

This work was funded by a Wellcome Trust grant (106698) to the Thailand Major Overseas Programme. The funders had no role in study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

## Ethical approval

Ethical approval was not required.

## Conflict of interest

The authors declare no conflicts of interest.

## Acknowledgements

This publication made use of the PubMLST website (<https://pubmlst.org/>) developed by Keith Jolley (Jolley and Maiden, 2010) and sited at the University of Oxford. The development of that website was funded by the Wellcome Trust. We acknowledge the laboratory staff who assisted with this project, including Jiraporn Tangmanakit and Pattaraporn Hinfontong at SMRU. We also thank Dr Manivanh Vongsouvath, Mahosot Microbiology Laboratory Director, Professor Paul Newton, Director of LOMWRU, and the staff of Mahosot Hospital and Lao Ministry of Health for their help and support. This work was funded by a Wellcome Trust grant (106698) to the Thailand Major Overseas Programme.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.ijid.2020.03.081>.

## References

- Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 2012;19(5):455–77.
- Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. *Expert Rev Vaccines* 2017;16(4):313–28.
- Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res* 2015;43(3):e15.
- Deghmane A-E, Hong E, Taha M-K. Emergence of meningococci with reduced susceptibility to third-generation cephalosporins. *J Antimicrob Chemother* 2017;72(1):95–8.
- Enriquez R, Abad R, Salcedo C, Pérez S, Vázquez JA. Fluoroquinolone resistance in *Neisseria meningitidis* in Spain. *J Antimicrob Chemother* 2008;61(2):286–90.
- Feil EJ, Maiden MC, Achtman M, Spratt BG. The relative contributions of recombination and mutation to the divergence of clones of *Neisseria meningitidis*. *Mol Biol Evol* 1999;16(11):1496–502.

- Fuller DG, Duke T, Shann F, Curtis N. Antibiotic treatment for bacterial meningitis in children in developing countries. *Ann Trop Paediatr* 2003;23(4):233–53.
- Galimand M, Gerbaud G, Guibourdenche M, Riou JY, Courvalin P. High-level chloramphenicol resistance in *Neisseria meningitidis*. *N Engl J Med* 1998;339(13):868–74.
- Gorla MC, Pinhata JMW, Dias UJ, de Moraes C, Lemos AP. Surveillance of antimicrobial resistance in *Neisseria meningitidis* strains isolated from invasive cases in Brazil from 2009 to 2016. *J Med Microbiol* 2018;67(6):750–6.
- Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. *Vaccine* 2009;27(Suppl. 2):B51–63.
- Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, et al. Description and nomenclature of *Neisseria meningitidis* capsule locus. *Emerg Infect Dis* 2013;19(4):566–73.
- Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcén P, Unemo M. Antibiotic susceptibility and characteristics of *Neisseria meningitidis* isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives. *Antimicrob Agents Chemother* 2009;53(4):1561–6.
- Jolley KA, Maiden MCJ. BIGSdb: Scalable analysis of bacterial genome variation at the population level. *BMC Bioinformatics* 2010;11:595.
- Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermini LS, ModelFinder: fast model selection for accurate phylogenetic estimates. *Nat Methods* 2017;14(6):587–9.
- Khennavong M, Davone V, Vongsouvath M, Phetsouvanh R, Silisouk J, Rattana O, et al. Urine antibiotic activity in patients presenting to hospitals in Laos: implications for worsening antibiotic resistance. *Am J Trop Med Hyg* 2011;85(2):295–302.
- McGill F, Heyderman RS, Michael BD, Defres S, Beeching NJ, Borrow R, et al. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. *J Infect* 2016;72(4):405–38.
- Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* 2015;32(1):268–74.
- Pancharoen C, Hongsiriwon S, Swasdichai K, Puthanakit T, Tangsathapornpong A, Lolekha S, et al. Epidemiology of invasive meningococcal disease in 13 government hospitals in Thailand, 1994–1999. *Southeast Asian J Trop Med Public Health* 2000;31(4):708–11.
- Peng J, Yang L, Yang F, Yang J, Yan Y, Nie H, et al. Characterization of ST-4821 complex, a unique *Neisseria meningitidis* clone. *Genomics* 2008;91(1):78–87.
- Raclouz VN, Luiz SJD. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. *BMC Infect Dis* 2010;10:175.
- Seemann T. Abriicate [Internet]. Github. Available from: <https://github.com/tseemann/abriicate> [cited 19 December 2018].
- Seemann T. Snippy [Internet]. Github. Available from: <https://github.com/tseemann/snippy> [cited 11 December 2018].
- Shultz TR, Tapsall JW, White PA, Ryan CS, Lyras D, Rood JI, et al. Chloramphenicol-resistant *Neisseria meningitidis* containing catP isolated in Australia. *J Antimicrob Chemother* 2003;52(5):856–9.
- Skoczynska A, Alonso J-M, Taha M-K. Ciprofloxacin resistance in *Neisseria meningitidis*, France. *Emerg Infect Dis* 2008;14(8):1322–3.
- Taha M-K, Vázquez JA, Hong E, Bennett DE, Bertrand S, Bukovski S, et al. Target gene sequencing to characterize the penicillin G susceptibility of *Neisseria meningitidis*. *Antimicrob Agents Chemother* 2007;51(8):2784–92.
- Tran TX, Le TT, Trieu LP, Austin CM, Van Quyen D, Nguyen HM. Whole-genome sequencing and characterization of an antibiotic resistant *Neisseria meningitidis* B isolate from a military unit in Vietnam. *Ann Clin Microbiol Antimicrob* 2019;18(1):16.
- Tsang RSW, Ahmad T, Jamieson FB, Tyrrell GJ. WGS analysis of a penicillin-resistant *Neisseria meningitidis* strain containing a chromosomal ROB-1  $\beta$ -lactamase gene. *J Antimicrob Chemother* 2019;74(1):22–8.
- Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis* 2004;39(9):1267–84.
- Vyse A, Anonychuk A, Jäkel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. *Expert Rev Anti Infect Ther* 2013;11(6):597–604.
- Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M. Meningococcal disease in Asia: an under-recognized public health burden. *Epidemiol Infect* 2011;139(7):967–85.
- Wayne PA, Clinical and Laboratory Standards Institute, CLSI. Performance standards for antimicrobial susceptibility testing. 28th ed. 2018 CLSI supplement M100.
- Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 2012;67(11):2640–4.